147 related articles for article (PubMed ID: 32292860)
1. Relapsed ocular squamous surface neoplasia treated with topical interferon alfa-2b.
Rocha-de-Lossada C; Alba-Linero C; Borroni D; Rachwani-Anil R; Zamorano-Martín F; Rodríguez-Calvo-de-Mora M
Rom J Ophthalmol; 2020; 64(1):62-65. PubMed ID: 32292860
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b.
Boehm MD; Huang AJ
Ophthalmology; 2004 Sep; 111(9):1755-61. PubMed ID: 15350333
[TBL] [Abstract][Full Text] [Related]
3. Treatment of conjunctival and corneal epithelial neoplasia with retinoic acid and topical interferon alfa-2b: long-term follow-up.
Krilis M; Tsang H; Coroneo M
Ophthalmology; 2012 Oct; 119(10):1969-73. PubMed ID: 22704834
[TBL] [Abstract][Full Text] [Related]
4. Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
Karp CL; Moore JK; Rosa RH
Ophthalmology; 2001 Jun; 108(6):1093-8. PubMed ID: 11382635
[TBL] [Abstract][Full Text] [Related]
5. Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia.
Vann RR; Karp CL
Ophthalmology; 1999 Jan; 106(1):91-7. PubMed ID: 9917787
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of conjunctival and corneal intraepithelial neoplasia treated with topical interferon alfa-2b.
Schechter BA; Koreishi AF; Karp CL; Feuer W
Ophthalmology; 2008 Aug; 115(8):1291-6, 1296.e1. PubMed ID: 18187195
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy.
Alvarado-Castillo B; Santa Cruz-Pavlovich FJ; Gonzalez-Castillo C; Vidal-Paredes IA; Garcia-Benavides L; Rosales-Gradilla ME; Navarro-Partida J
BMC Ophthalmol; 2023 Jul; 23(1):335. PubMed ID: 37501105
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Topical 5-Fluorouracil and Interferon Alfa-2b as Primary Treatment Modalities for Ocular Surface Squamous Neoplasia.
Venkateswaran N; Mercado C; Galor A; Karp CL
Am J Ophthalmol; 2019 Mar; 199():216-222. PubMed ID: 30471241
[TBL] [Abstract][Full Text] [Related]
9. Topical Interferon α-2b as a Single Therapy for Primary Ocular Surface Squamous Neoplasia.
Kusumesh R; Ambastha A; Sinha B; Kumar R
Asia Pac J Ophthalmol (Phila); 2015; 4(5):279-82. PubMed ID: 26176194
[TBL] [Abstract][Full Text] [Related]
10. A case of conjunctiva-cornea intraepithelial neoplasia successfully treated with topical mitomycin C and interferon alfa-2b in cycles.
Di Pascuale MA; Espana EM; Tseng SC
Cornea; 2004 Jan; 23(1):89-92. PubMed ID: 14701965
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b.
Pérez-García P; Burgos-Blasco B; Gómez-Calleja V; Vidal-Villegas B; Méndez-Fernández R; Gegúndez-Fernández JA; Díaz-Valle D
J Oncol Pharm Pract; 2023 Jun; 29(4):975-979. PubMed ID: 36131486
[TBL] [Abstract][Full Text] [Related]
12. Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b.
Schechter BA; Schrier A; Nagler RS; Smith EF; Velasquez GE
Cornea; 2002 Jan; 21(1):6-11. PubMed ID: 11805499
[TBL] [Abstract][Full Text] [Related]
13. Interferon Alfa-2b for Pigmented Ocular Surface Squamous Neoplasia: A Report of 8 Lesions.
Kaliki S; Sharma A; Vempuluru VS
Cornea; 2021 Feb; 40(2):142-146. PubMed ID: 32355112
[TBL] [Abstract][Full Text] [Related]
14. Topical interferon alfa-2b for management of ocular surface squamous neoplasia in 23 cases: outcomes based on American Joint Committee on Cancer classification.
Shah SU; Kaliki S; Kim HJ; Lally SE; Shields JA; Shields CL
Arch Ophthalmol; 2012 Feb; 130(2):159-64. PubMed ID: 22332208
[TBL] [Abstract][Full Text] [Related]
15. The treatment of recurrent conjunctival and corneal intraepithelial neoplasia with interferon alfa-2b and retinoic acid: ~9 years' follow-up on tumor control.
Ip MH; Tat L; Coroneo MT
Ocul Surf; 2020 Jul; 18(3):354-359. PubMed ID: 32311432
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for ocular surface squamous neoplasia recurrence after treatment with topical mitomycin C and interferon alpha-2b.
Besley J; Pappalardo J; Lee GA; Hirst LW; Vincent SJ
Am J Ophthalmol; 2014 Feb; 157(2):287-293.e2. PubMed ID: 24184223
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of 9 squamous epithelial carcinoma in situ lesions of the conjunctiva (CIN) with mitomycin C eyedrops in cytological and DNA image cytometric control].
Cartsburg O; Kersten A; Sundmacher R; Nadjari B; Pomjanski N; Böcking A
Klin Monbl Augenheilkd; 2001 Jun; 218(6):429-34. PubMed ID: 11488009
[TBL] [Abstract][Full Text] [Related]
18. Surgical versus medical treatment of ocular surface squamous neoplasia: a comparison of recurrences and complications.
Nanji AA; Moon CS; Galor A; Sein J; Oellers P; Karp CL
Ophthalmology; 2014 May; 121(5):994-1000. PubMed ID: 24411578
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of topical mitomycin C 0.02% for primary and recurrent conjunctival-corneal intraepithelial neoplasia.
Ballalai PL; Erwenne CM; Martins MC; Lowen MS; Barros JN
Ophthalmic Plast Reconstr Surg; 2009; 25(4):296-9. PubMed ID: 19617789
[TBL] [Abstract][Full Text] [Related]
20. Recurrent intraepithelial neoplasia treatment.
Schechter BA; Nagler RS; Schrier A
Ophthalmology; 2005 Jul; 112(7):1319; author reply 1319. PubMed ID: 15993243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
